Fabry Disease Therapeutics

1. Galafold patent expiration

Treatment: The treatment of fabry patients; A method of reducing left ventricular mass index (lvmi) in a fabry patient by administering migalastat

GALAFOLD's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US12280042 AMICUS Methods of treating fabry patients having renal impairment
May, 2038

(12 years from now)

US11903938 AMICUS Methods of treating Fabry patients having renal impairment
Aug, 2038

(12 years from now)

US12042489 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11304940 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US12109205 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11612594 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US12042488 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11622962 AMICUS Methods of treating Fabry patients having renal impairment
Mar, 2039

(13 years from now)

US11357764 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11376244 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11612593 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11357765 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11426396 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11633387 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11826360 AMICUS Methods of treating Fabry patients having renal impairment
Feb, 2039

(12 years from now)

US11786516 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000011 AMICUS Methods for treatment of Fabry disease
May, 2027

(1 year, 2 months from now)

US10383864 AMICUS Methods for treatment of Fabry disease
May, 2027

(1 year, 2 months from now)

US10471053 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US10076514 AMICUS Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
Mar, 2037

(11 years from now)

US8592362 AMICUS Method to predict response to pharmacological chaperone treatment of diseases
Feb, 2029

(2 years from now)

US11642334 AMICUS Methods of treating Fabry patients having renal impairment
Feb, 2039

(13 years from now)

US9095584 AMICUS Method to predict response to pharmacological chaperone treatment of diseases
Feb, 2029

(2 years from now)

US9999618 AMICUS Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Apr, 2028

(2 years from now)

US10813921 AMICUS Method to predict response to pharmacological chaperone treatment of diseases
Feb, 2029

(2 years from now)

US10857141 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US10849890 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

USRE48608 AMICUS Method to predict response to pharmacological chaperone treatment of diseases
Oct, 2031

(5 years from now)

US10799491 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US10806727 AMICUS Methods of treating fabry patients having renal impairment
May, 2038

(12 years from now)

US11458128 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US10406143 AMICUS Methods for treatment of fabry disease
May, 2027

(1 year, 2 months from now)

US10525045 AMICUS Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Apr, 2028

(2 years from now)

US9987263 AMICUS Methods for treatment of Fabry disease
May, 2027

(1 year, 2 months from now)

US9480682 AMICUS Methods for treatment of Fabry disease
May, 2027

(1 year, 2 months from now)

US11234972 AMICUS Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
Mar, 2037

(11 years from now)

US11278538 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11278537 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11278536 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11278539 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11278540 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US10925866 AMICUS Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Apr, 2028

(2 years from now)

US10251873 AMICUS Methods of treating fabry patients having renal impairment
May, 2038

(12 years from now)

US11633388 AMICUS Methods of treating Fabry patients having renal impairment
Mar, 2039

(13 years from now)

US11033538 AMICUS Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Apr, 2028

(2 years from now)

US12042490 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11357761 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11357762 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11357763 AMICUS Methods of treating fabry patients having renal impairment
May, 2038

(12 years from now)

US11357784 AMICUS Use of migalastat for treating Fabry disease in pregnant patients
Feb, 2039

(12 years from now)

US11666564 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US10849889 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US10857142 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11389437 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11389436 AMICUS Methods of treating fabry patients having renal impairment
May, 2038

(12 years from now)

US10874657 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US10874655 AMICUS Methods of treating fabry patients having renal impairment
May, 2038

(12 years from now)

US10874656 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US10792278 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US10792279 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11833164 AMICUS Methods of treating Fabry disease in patients having a mutation in the GLA gene
Jan, 2042

(15 years from now)

US11813255 AMICUS Methods of treating Fabry patients having renal impairment
May, 2038

(12 years from now)

US11241422 AMICUS Methods for treatment of Fabry disease
May, 2027

(1 year, 2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 10, 2023
Orphan Drug Exclusivity(ODE-205) Aug 10, 2025

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Dosage: CAPSULE

How can I launch a generic of GALAFOLD before it's drug patent expiration?
More Information on Dosage

GALAFOLD family patents

Family Patents